Fig. 2From: Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institutionFlow diagram of a phase 2 study with neoadjuvant IMRT. Forty-seven patients (95.9%) completed NACIMRT with gemcitabine and 55.1% (29/49) of the patients underwent pancreatectomyBack to article page